BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25640698)

  • 1. Repositioning Potential of PAK4 to Osteoclastic Bone Resorption.
    Choi SW; Yeon JT; Ryu BJ; Kim KJ; Moon SH; Lee H; Lee MS; Lee SY; Heo JC; Park SJ; Kim SH
    J Bone Miner Res; 2015 Aug; 30(8):1494-507. PubMed ID: 25640698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
    Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
    J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.
    Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J
    Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
    Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.
    Lee MS; Kim HS; Yeon JT; Choi SW; Chun CH; Kwak HB; Oh J
    J Immunol; 2009 Sep; 183(5):3390-9. PubMed ID: 19641137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
    Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
    J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
    Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to Investigate the Role of Rho GTPases in Osteoclast Function.
    Morel A; Blangy A; Vives V
    Methods Mol Biol; 2018; 1821():219-233. PubMed ID: 30062415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.
    Katagiri M; Ogasawara T; Hoshi K; Chikazu D; Kimoto A; Noguchi M; Sasamata M; Harada S; Akama H; Tazaki H; Chung UI; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2006 Feb; 21(2):219-27. PubMed ID: 16418777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
    de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
    Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity.
    Selamat W; Tay PL; Baskaran Y; Manser E
    PLoS One; 2015; 10(6):e0129634. PubMed ID: 26068882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
    Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
    Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
    Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.